Evaluating Perampanel to Prevent Seizures After Cardiac Arrest in Adults

What this Trial Is About

Brain injury is a leading cause of death and disability for patients who survive cardiac arrest resuscitation, with seizures occurring in up to one-third of these patients. This trial is investigating the safety and feasibility of using perampanel to prevent post-cardiac arrest status epilepticus, a condition where seizures are difficult to control and often fatal. The study is a pilot randomized placebo-controlled trial focused on adults admitted to the intensive care unit after cardiac arrest. Participants will be randomly assigned to receive either perampanel or a placebo. Those in the perampanel group will receive an oral loading dose of 24 mg at randomization followed by 8 mg daily for four more days, totaling five days of treatment. The placebo group will receive a matching oral placebo load and daily doses over the same five-day period. The trial aims to evaluate safety by monitoring for severe adverse events during this treatment window. During the study, participants will be closely monitored in the intensive care unit with evaluations including seizure incidence, seizure frequency, time to seizure control, the number of anti-seizure medications needed, duration of anesthetic treatment for seizures, and time to awakening from coma. Safety and tolerability will be assessed over seven days, and neurological function will be evaluated at 180 days. The trials outcomes will help determine the feasibility of preventing seizures after cardiac arrest using perampanel.

PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest